Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Subscribe To Our Newsletter & Stay Updated
